Helvetica Chimica Acta (2018)
Update date:2022-08-02
Topics:
Herzog, Antoine F.
Schneider, Elia M.
Stark, Wendelin J.
The use of a p-nitrobenzyloxycarbonyl (pNZ) protecting group on the FDA-approved lung cancer drug gemcitabine affords a caged drug with very low in vitro toxicity in a human model cell line (A549). To activate this type of caged potent drug, simultaneous presence of two items is needed: platinum nanoparticles and hydrogen-containing gas mixtures. This combination may later allow a more precise and controlled local delivery of highly potent cytostatic compounds, and may eventually permit reduction of the severe side effects of such chemotherapy treatments. Hydrogen, though an unusual medical agent, is well tolerated, and here used mixtures are derived from diving (deep diving gas). Pt nanoparticles at here used concentrations may eventually be locally deposited into the lungs through minimal invasive inhalation. We demonstrate the use of hydrogen as an on/off uncaging switch and show repeated use of the Pt nanoparticles for a series of uncaging events.
Zhengzhou Minzhong Pharmaceutical Co.,ltd
Contact:0086-371-65797115
Address:15/F,Jiangshan Bldg, NO.126 Huanghe Road,Zhengzhou, China
website:http://www.easchem.com
Contact:+86-731-89722861 89722891
Address:2/F-4/Bld Colorful Palace, No.605 Changsha Ave, Yuhua Area Changsha Hunan China.
Chengdu Green technology Co.,Ltd.
Contact:86-28-82608355
Address:C9 ,Economic Headquarters, Economic Development Zone, Chengdu.
HANGZHOU YUNUO CHEMICAL CO.,LTD
website:http://www.yunuochem.com
Contact:0571-83715115
Address:hangzhou
Ningxia Soochow Agrochemical Limited Company
Contact:(+86）0512 6320 8190
Address:wujiang
Doi:10.1039/b800815a
(2008)Doi:10.1016/j.bmcl.2007.12.067
(2008)Doi:10.1016/S0040-4039(00)95015-9
(1985)Doi:10.1016/j.carres.2019.107832
(2019)Doi:10.1021/om049443s
(2005)Doi:10.1002/anie.200705822
(2008)
